Biologics represented 5% of the drugs prescribed in the U.S. in 2024, but they accounted for more than half of the country’s ...

FDA aims to speed biosimilar approvals to increase competition, but experts warn drug prices may not drop quickly.

Biologics are complex medications produced through biological processes or from living organisms such as proteins and genes. Biosimilars are what they sound like — similar to, but not the same as, an ...

The Food and Drug Administration (FDA) has issued new draft guidance signaling a policy shift toward reducing the need for comparative efficacy ...

The U.S. stands at a crossroads in light of rising drug prices and it is unclear what the future will hold in answer to the rising drug costs. Biologic medicines have rapidly expanded available ...

Tyruko (R) was developed by Polpharma Biologics and will be commercialized in the U.S. by its collaboration partner Sandoz, under an exclusive global license agreement. The launch marks a significant ...

Eydenzelt is subjecting Eylea to further biosimilar erosion, though Regeneron hopes to offset this with two new approvals for ...

The main opportunities in the Biosimilar Contract Manufacturing Market include the growing demand driven by the rise in chronic diseases, the patent expirations of biologics boosting biosimilar ...

Biocon Biologics has commercialized nine biosimilars from its pipeline of 20 products in key emerging markets and advanced markets like U.S., Europe, Australia, Canada, and Japan. It's pipeline has ...

BRIDGEWATER, N.J. and BENGALURU, India, Feb. 24, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of ...

Polpharma Biologics S.A. (“Polpharma Biologics”) announces a global (except for Middle East & North Africa) licensing agreement with Fresenius Kabi for the commercialization of PB016, a proposed ...